Normal view
-
MedPageToday.com - medical news for physicians

-
Are GLP-1 Drugs Linked to Erectile Dysfunction?
(MedPage Today) -- GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 diabetes, a target trial emulation suggested. Using U.S. electronic health record data, the incidence of...
-
Journal of Medical Internet Research
-
Validation of the Updated Digital Health Literacy Instrument and Development of a Short Form: Online Survey Study of the General Population
Background: The digital health literacy instrument (DHLI) was developed in 2017 to measure individuals’ ability to access, understand, evaluate, and apply online health information. Since that time, digital health has shifted from desktop-based internet use to mobile devices, and there has been a rapidly expanding range of health apps. Additionally, heightened privacy and data security requirements have increased the complexity of user competencies needed to engage with digital health tools. The
Validation of the Updated Digital Health Literacy Instrument and Development of a Short Form: Online Survey Study of the General Population
-
AI News
-
JPMorgan begins tracking how employees use AI at work
Banking house JPMorgan Chase is asking its roughly 65,000 engineers and technologists to use AI tools as part of their regular workflow. Business Insider reported that managers are tracking how often staff use these tools. That use may also influence performance reviews. The report states employees are encouraged to use tools like ChatGPT and Claude Code when writing code, reviewing documents, or handling routine tasks. Internal systems then classify workers based on their level of use. Some are
JPMorgan begins tracking how employees use AI at work
Banking house JPMorgan Chase is asking its roughly 65,000 engineers and technologists to use AI tools as part of their regular workflow. Business Insider reported that managers are tracking how often staff use these tools. That use may also influence performance reviews.
The report states employees are encouraged to use tools like ChatGPT and Claude Code when writing code, reviewing documents, or handling routine tasks. Internal systems then classify workers based on their level of use. Some are labelled “light users,” while others fall into a “heavy user” category.
JPMorgan has been using in fraud detection and risk analysis. What stands out here is not the technology itself, but how it is being woven into day-to-day expectations for staff.
According to internal materials cited by Business Insider, managers are paying close attention to how employees use AI tools.
JPMorgan shows AI adoption in banks
Many companies have spent the past two years rolling out AI tools in departments. In most cases, adoption has been uneven. Some teams experiment heavily, while others stick to existing workflows.
JPMorgan is treating AI as a standard part of the job. That creates a more uniform level of adoption in teams. In the past, performance reviews focused on output and accuracy. Now, they may also include how effectively employees use AI tools to reach those results.
That raises a practical question for large organisations. If AI can reduce the time needed for certain tasks, should employees be expected to produce more work in the same amount of time?
Keeping pace with internal change
By tracking use, the bank may be trying to avoid a familiar problem in enterprise software rollouts. Tools are deployed, but adoption is slow, limiting their impact. Making AI part of performance reviews creates a stronger incentive to engage with the technology. It also suggests that AI literacy is becoming a baseline skill, similar to how spreadsheets or code tools became standard over time.
New challenges include employees feeling pressure to use AI even in cases where it does not clearly improve the outcome. There is also the matter of how to measure “good” use, as opposed to simply frequent use.
JPMorgan’s AI risks and efficiency gains
Banks operate in a regulated environment, where introducing AI into more workflows increases the need for oversight.
Tools like ChatGPT and Claude Code can help summarise information or generate drafts, but they can also produce incorrect or incomplete results. That means employees still need to verify outputs before using them in decision-making or client-facing work.
JPMorgan has developed internal controls for AI systems in areas like trading and risk. Expanding use in a broader group of employees may require similar safeguards, creating a situation for the bank in which it wants to improve efficiency, but also needs to ensure that heavier AI use does not introduce new risks.
Other financial institutions are likely watching closely. If tying AI use to performance leads to measurable gains in productivity, similar models may spread in the sector.
The bank’s approach may reshape how companies hire and train employees, and skills like prompt writing and output checks could become part of standard job requirements. JPMorgan’ approach suggests that this change is already underway, at least in banking.
(Photo by IKECHUKWU JULIUS UGWU)
See also: RPA matters, but AI changes how automation works
Want to experience the full spectrum of enterprise technology innovation? Join TechEx in Amsterdam, California, and London. Covering AI, Big Data, Cyber Security, IoT, Digital Transformation, Intelligent Automation, Edge Computing, and Data Centres, TechEx brings together global leaders to share real-world use cases and in-depth insights. Click here for more information.
AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.
The post JPMorgan begins tracking how employees use AI at work appeared first on AI News.
-
Omics In Lung
-
Artificial intelligence and machine learning in non-small cell lung cancer: the current state of the science on multi-omic applications
BMC Med Res Methodol. 2026 Mar 9. doi: 10.1186/s12874-026-02821-4. Online ahead of print.NO ABSTRACTPMID:41803732 | DOI:10.1186/s12874-026-02821-4
Artificial intelligence and machine learning in non-small cell lung cancer: the current state of the science on multi-omic applications
BMC Med Res Methodol. 2026 Mar 9. doi: 10.1186/s12874-026-02821-4. Online ahead of print.
NO ABSTRACT
PMID:41803732 | DOI:10.1186/s12874-026-02821-4
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
A viable human lung cancer tissue collection (LCTC) to accelerate translational research
Cancer Treat Res Commun. 2026 Mar 2;47:101162. doi: 10.1016/j.ctarc.2026.101162. Online ahead of print.ABSTRACTBACKGROUND: The collection of clinical data and patient tumor specimens in institutional repositories is essential to accelerate translational research in lung cancer, linking laboratory findings with patient outcomes. These resources allow investigators to explore tumor heterogeneity, analyze therapeutic profiles and, more recently, generate patient-derived models of cancer. Given the
A viable human lung cancer tissue collection (LCTC) to accelerate translational research
Cancer Treat Res Commun. 2026 Mar 2;47:101162. doi: 10.1016/j.ctarc.2026.101162. Online ahead of print.
ABSTRACT
BACKGROUND: The collection of clinical data and patient tumor specimens in institutional repositories is essential to accelerate translational research in lung cancer, linking laboratory findings with patient outcomes. These resources allow investigators to explore tumor heterogeneity, analyze therapeutic profiles and, more recently, generate patient-derived models of cancer. Given the plethora of therapies in clinical use or under investigation, it is critical to establish tissue collection programs that support the identification of predictive biomarkers of drug sensitivity to define patient subgroups that may benefit from tailored therapeutic strategies. However, access to high-quality viable specimens remains limited.
METHODS: We established a multidisciplinary program -the Lung Cancer Tissue Collection (LCTC) study- to prospectively collect viable human specimens and clinical data. Samples can be collected post-diagnosis and at multiple treatment time points, preserving material for future studies.
RESULTS: In the first 24 months of the LCTC study, we enrolled 158 patients and collected over 700 specimens from patients with lung cancer. EGFR and KRAS mutations were the most frequently identified oncogenic drivers, mirroring frequencies reported in public datasets. We achieved a 60 % success rate in cryopreservation -measured by the proportion of patient-derived organoids growing after tissue thawing and processing- highlighting the feasibility of our program.
CONCLUSIONS: The LCTC biobank captures the molecular and clinical diversity of lung cancer, providing a clinically annotated resource of viable tissue and longitudinal blood specimens. This platform enables patient-derived modeling and multi-omic and functional studies to investigate tumor biology, treatment response, and resistance, supporting biomarker discovery and precision medicine.
PMID:41797251 | DOI:10.1016/j.ctarc.2026.101162
-
(Multiomics OR Omics) AND (Pancreatic)
-
Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI)
Int J Clin Oncol. 2026 Mar 6. doi: 10.1007/s10147-026-03001-6. Online ahead of print.ABSTRACTBACKGROUND: Early detection of cancer and precise recurrence monitoring remain major unmet needs in oncology. Conventional screening is limited to a few cancer types, leaving nearly half of cancers without established programs. Multi-cancer early detection (MCED) tests based on circulating tumor biomarkers have shown promise, but sensitivity for early-stage remains a challenge. In parallel, detection of
Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI)
Int J Clin Oncol. 2026 Mar 6. doi: 10.1007/s10147-026-03001-6. Online ahead of print.
ABSTRACT
BACKGROUND: Early detection of cancer and precise recurrence monitoring remain major unmet needs in oncology. Conventional screening is limited to a few cancer types, leaving nearly half of cancers without established programs. Multi-cancer early detection (MCED) tests based on circulating tumor biomarkers have shown promise, but sensitivity for early-stage remains a challenge. In parallel, detection of molecular residual disease (MRD) using circulating tumor DNA (ctDNA) has emerged as a powerful prognostic and predictive tool, though current assays remain limited in sensitivity and specificity. This study aims to integrate multi-omics data to develop more refined and highly sensitive MCED and MRD assays.
METHODS: This study leverages clinical information and biospecimens from patients with cancer and cancer-naïve individuals. Samples from patients with cancers will be derived from the MONSTAR-SCREEN-3 study, while those from cancer-naïve individuals will be obtained from the Tohoku Medical Megabank Project. Comprehensive analyses will include whole-genome sequencing (WGS), whole-exome sequencing (WES), whole-transcriptome sequencing (WTS), proteomics, metabolomics, and microbiome profiling using stool and saliva. Artificial intelligence (AI)-based multi-omics integration will be performed to develop novel MCED and MRD assays and to evaluate their clinical performance. The primary endpoints are the sensitivity and specificity of MCED and MRD assays.
DISCUSSION: This is the first large-scale study to integrate comprehensive multi-omics profiling with AI for MCED and MRD assay development. The findings are expected to advance precision oncology by improving early diagnosis and recurrence monitoring.
TRIAL REGISTRATION: UMIN000053815, approved by the Institutional Review Board of the National Cancer Center Hospital East.
PMID:41790338 | DOI:10.1007/s10147-026-03001-6
-
Journal of Medical Internet Research
-
Interorganizational Mechanisms for Developing and Implementing Clinical Decision Support Systems in Primary Care: Exploratory, Qualitative Case Study
Background: Clinical decision support systems (CDSS) have the potential to improve patient safety and reduce costs in primary care. However, CDSS adoption remains limited due to development and implementation challenges. CDSSs are complex interventions involving multiple interacting components that require technological innovation and behavioral and organizational change. Additionally, the primary care context is considered a complex system with high care demand, fragmented structures, and many
Interorganizational Mechanisms for Developing and Implementing Clinical Decision Support Systems in Primary Care: Exploratory, Qualitative Case Study
-
STAT

-
STAT+: Patient health data as a public utility: A former ARPA-H data chief explains
Last year, the Department of Health and Human Services published a sweeping document that described the agency’s approach to real-world data. Historically, health and biomedical data has been intentionally manufactured, the output of carefully designed clinical trials. But in a digitized world, it can instead be mined — and patients’ interactions with the health care system are the natural resource. The Living HHS Open Data Plan, published in July, proposed treating data more like we do other
STAT+: Patient health data as a public utility: A former ARPA-H data chief explains
Last year, the Department of Health and Human Services published a sweeping document that described the agency’s approach to real-world data. Historically, health and biomedical data has been intentionally manufactured, the output of carefully designed clinical trials. But in a digitized world, it can instead be mined — and patients’ interactions with the health care system are the natural resource.
The Living HHS Open Data Plan, published in July, proposed treating data more like we do other natural resources. “At the core” of the plan, it reads, “lies the concept that data is a ‘public utility’ for good that powers scientific advancement, innovation, and progress.” Patients should have access to that utility, HHS argued, but it should also be easier to leverage for research, safety monitoring, and other uses in the public interest.
On Thursday, a group of researchers, former agency officials, and health data companies continued that call in a policy forum published in Science. If health data is to be treated like a public utility, they write, it should be similarly governed. Like electricity, the system would have to involve customers, local distribution companies, transmission companies, generators, and the government.
Continue to STAT+ to read the full story…


© Adobe
-
MedPageToday.com - medical news for physicians

-
Genomically Matched Cancer Therapies Only as Good as Supporting Evidence
(MedPage Today) -- Patients with advanced/refractory cancers treated with genomically matched therapies had better overall survival only when the treatments had support from prospective studies, a large multicenter cohort study from Australia showed...
Genomically Matched Cancer Therapies Only as Good as Supporting Evidence
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Systematic Identification of Molecular Signatures Dictating Therapeutic Effects of Clinically First-Line Chemotherapy Regimens for Human Gastric Cancer Patients Based on Organoid Model
MedComm (2020). 2026 Mar 2;7(3):e70656. doi: 10.1002/mco2.70656. eCollection 2026 Mar.ABSTRACTChemotherapy is the mainstay in the treatment of advanced gastric cancer (GC); yet, GC showed diverse responses to first-line chemotherapy regimens and the underlying molecular basis is still not clear. Here, we established a system that combined organoid-based chemotherapy regimen screening and transcriptome-based evaluation to identify underlying molecular signatures of different responses to chemothe
Systematic Identification of Molecular Signatures Dictating Therapeutic Effects of Clinically First-Line Chemotherapy Regimens for Human Gastric Cancer Patients Based on Organoid Model
MedComm (2020). 2026 Mar 2;7(3):e70656. doi: 10.1002/mco2.70656. eCollection 2026 Mar.
ABSTRACT
Chemotherapy is the mainstay in the treatment of advanced gastric cancer (GC); yet, GC showed diverse responses to first-line chemotherapy regimens and the underlying molecular basis is still not clear. Here, we established a system that combined organoid-based chemotherapy regimen screening and transcriptome-based evaluation to identify underlying molecular signatures of different responses to chemotherapy. We generated 19 GC patient-derived organoids (PDOs) from surgically resected specimens with corresponding histological characteristics of parent tumors and tested all of the five most commonly used first-line chemotherapy regimens. Based on the treatment responses, PDOs were classified into double-sensitive, single-sensitive, and not-sensitive groups. PDOs that responded well to chemotherapy presented high expression levels of the P53 pathway genes and low expression levels of cell proliferative activity genes. Furthermore, the chemotherapy-based tumor classification of GC was established. The GC tumor classification was verified by multi-omics features from the TCGA dataset and public drug response datasets. In conclusion, this study systematically evaluated clinical chemotherapy regimens for GC and identified chemotherapy response-associated molecular signatures based on human GC organoids, which are beneficial to the precise treatments of GC.
PMID:41782964 | PMC:PMC12954136 | DOI:10.1002/mco2.70656
-
Journal of Medical Internet Research
-
AI Triage in Primary Care: Building Safer and More Equitable Real-World Evidence
Artificial intelligence triage in general practice is developing rapidly within the primary care digital transformation, promising efficiency gains and safety standardization in overwhelmed primary care systems. However, current evidence is drawn from retrospective validations, emergency settings, or vignettes, with scant evaluation of real-world outcomes and almost no equity-stratified safety data, despite known disparities across age, ethnicity, language, and deprivation. From a sociotechnical
AI Triage in Primary Care: Building Safer and More Equitable Real-World Evidence
-
Journal of Medical Internet Research
-
Mental Health Professionals’ Perceptions of Benefits and Disadvantages of Telehealth: International Mixed Methods Study
Background: Telehealth has become an integral component of mental health care delivery worldwide. Understanding provider perceptions is essential to guiding its continued implementation. Objective: This international study used quantitative and qualitative methodologies to examine and broaden our understanding of the benefits and concerns related to telehealth for mental health care. Methods: An internet-based survey was conducted during the COVID-19 pandemic between November 11 and December 18,
Mental Health Professionals’ Perceptions of Benefits and Disadvantages of Telehealth: International Mixed Methods Study
-
MedPageToday.com - medical news for physicians

-
Rapid RSV Tests Can Cut Down on Unneeded Antibiotics, Study Suggests
(MedPage Today) -- Rapid antigen diagnostic testing to confirm respiratory syncytial virus (RSV) infections in young children was linked to fewer unnecessary antibiotic prescriptions in outpatient settings, according to an Italian retrospective...
Rapid RSV Tests Can Cut Down on Unneeded Antibiotics, Study Suggests
-
Journal of Medical Internet Research
-
Artificial Intelligence Applications in Medical Devices for Personalized Health Care Solutions: Systematic Review
Background: The integration of artificial intelligence (AI) in medical devices is transforming health care by enabling enhanced personalization and precision medicine. AI-driven medical devices can tailor treatments based on individual patient profiles, including genetic data, medical history, and physiological parameters. This advancement holds the potential to refine therapeutic interventions, improve patient outcomes, and streamline health care delivery. However, challenges such as data quali
Artificial Intelligence Applications in Medical Devices for Personalized Health Care Solutions: Systematic Review
-
cs.AI, q-bio.NC updates on arXiv.org
-
Architecting Trust in Artificial Epistemic Agents
arXiv:2603.02960v1 Announce Type: new Abstract: Large language models increasingly function as epistemic agents -- entities that can 1) autonomously pursue epistemic goals and 2) actively shape our shared knowledge environment. They curate the information we receive, often supplanting traditional search-based methods, and are frequently used to generate both personal and deeply specialized advice. How they perform these functions, including whether they are reliable and properly calibrated to b
Architecting Trust in Artificial Epistemic Agents
-
Nature - Issue - nature.com science feeds
-
Cancer blood tests are everywhere. Do they really work?
Nature, Published online: 04 March 2026; doi:10.1038/d41586-026-00661-2Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or delivering the wrong diagnosis.
Cancer blood tests are everywhere. Do they really work?
Nature, Published online: 04 March 2026; doi:10.1038/d41586-026-00661-2
Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or delivering the wrong diagnosis.-
Latest Science News -- ScienceDaily
-
Scientists find the genetic switch that makes pancreatic cancer resist chemotherapy
Scientists have identified a crucial molecular switch that decides whether pancreatic cancer cells resist chemotherapy or respond to it. The key player, a gene called GATA6, keeps tumours in a more structured and treatable form—but it gets shut down by an overactive KRAS-driven pathway. When researchers blocked that pathway, GATA6 levels rebounded and cancer cells became more sensitive to chemo. The discovery could help turn some of the toughest pancreatic tumours into ones doctors can better co
Scientists find the genetic switch that makes pancreatic cancer resist chemotherapy
-
InfoQ

-
From Central Control to Team Autonomy: Rethinking Infrastructure Delivery
Adidas engineers describe shifting from a centralized Infrastructure-as-Code model to a decentralized one. Five teams autonomously deployed over 81 new infrastructure stacks in two months, using layered IaC modules, automated pipelines, and shared frameworks. The redesign illustrates how to scale infrastructure delivery while maintaining governance at scale. By Leela Kumili
From Central Control to Team Autonomy: Rethinking Infrastructure Delivery
Adidas engineers describe shifting from a centralized Infrastructure-as-Code model to a decentralized one. Five teams autonomously deployed over 81 new infrastructure stacks in two months, using layered IaC modules, automated pipelines, and shared frameworks. The redesign illustrates how to scale infrastructure delivery while maintaining governance at scale.
By Leela Kumili-
AI News

-
Best AI security solutions 2026: Top enterprise platforms compared
Artificial intelligence is no longer just powering defensive cybersecurity tools, it is reshaping the entire threat landscape. AI is accelerating reconnaissance, improving the realism of phishing, automating malware mutation, and enabling adaptive attack techniques. At the same time, enterprises are embedding AI agents, copilots, and generative AI tools into everyday workflows. That dual dynamic has created a new category: AI security. AI security platforms focus on three primary challenge
Best AI security solutions 2026: Top enterprise platforms compared
Artificial intelligence is no longer just powering defensive cybersecurity tools, it is reshaping the entire threat landscape. AI is accelerating reconnaissance, improving the realism of phishing, automating malware mutation, and enabling adaptive attack techniques. At the same time, enterprises are embedding AI agents, copilots, and generative AI tools into everyday workflows.
That dual dynamic has created a new category: AI security.
AI security platforms focus on three primary challenges in 2026:
- Securing enterprise AI usage and prompt interactions
- Protecting AI models, agents, and infrastructure
- Defending against AI-powered cyber threats
Below are five of the strongest AI security solutions in 2026.
Check Point – AI-driven security

Check Point integrates AI security into its broader Infinity platform, covering network, cloud, endpoint, and AI usage in a unified architecture.
The core of the platform is ThreatCloud AI, which leverages more than 50 AI engines and intelligence from over 150,000 connected networks. Compromise indicators propagate across the platform within seconds, enabling coordinated defense across domains.
The platform addresses AI risk at multiple layers. GenAI Protect monitors employee interactions with generative AI tools, semantically analysing prompts to enforce data loss prevention policies in real time. This approach focuses on contextual classification rather than simple keyword matching.
Check Point also secures AI infrastructure and enhances security operations through Infinity AI Copilot. Independent testing has shown high efficacy against zero-day malware, and the platform has consistently ranked highly in hybrid firewall evaluations.
Best for: Enterprises seeking unified AI security across infrastructure, AI usage, and security operations.
CrowdStrike – AI security services

CrowdStrike extends its Falcon platform into AI protection by integrating telemetry from endpoints, identities, cloud workloads, and AI agent activity.
Falcon AIDR focuses specifically on defending against prompt injection and malicious manipulation of AI agents. It is designed to identify known prompt injection techniques while maintaining low latency, which is critical in production AI environments.
CrowdStrike also integrates AI assistants directly into security operations. Charlotte AI supports natural language threat investigation and automated triage, reinforcing the company’s vision of an AI-augmented SOC.
The approach is particularly strong for organisations already standardised on the Falcon ecosystem, allowing AI security capabilities to extend existing endpoint and cloud telemetry.
Best for: Organisations seeking integrated AI threat detection within an established endpoint-centric security architecture.
Cisco – AI defense

Cisco approaches AI security from a network-centric vantage point. Because it operates at the network layer, Cisco can inspect AI-related traffic across enterprise environments, including API calls and model interactions that may not be visible at the endpoint level.
Cisco AI Defense integrates into the broader Security Service Edge architecture. Recent enhancements include AI Bills of Materials to map dependencies within AI ecosystems, real-time guardrails for agentic systems, and red teaming simulations against AI workflows.
Cisco aligns its controls with established frameworks such as NIST AI Risk Management Framework and MITRE ATLAS. This emphasis on governance makes it attractive to enterprises operating in regulated industries.
Best for: Enterprises with strong Cisco network infrastructure seeking AI security embedded at the traffic and control layer.
Microsoft– AI-enhanced security ecosystem

Microsoft’s AI security advantage lies in scale. The company processes tens of trillions of security signals daily across its global infrastructure.
Security Copilot functions as an AI assistant embedded within Defender, Entra, Intune, and Purview. It automates alert triage, assists with natural language threat investigation, and orchestrates remediation actions.
Microsoft has also expanded AI security posture management to include multi-cloud environments, including AWS and Google Cloud AI services. This is particularly important for enterprises building AI models outside Azure.
For organisations already invested in Microsoft 365 enterprise licensing, AI-enhanced security capabilities can be layered into existing subscriptions without introducing additional vendor complexity.
Best for: Enterprises deeply aligned with Microsoft 365 and Defender ecosystems.
Okta– Identity security with AI risk context

As AI agents proliferate, identity becomes a primary attack surface. Many AI systems operate with high levels of privilege and autonomy.
Okta focuses specifically on identity governance in AI environments. Its architecture treats AI agents as first-class identities, applying authentication, authorisation, and lifecycle governance controls similar to those applied to human users.
Identity Security Posture Management identifies over-privileged accounts, including non-human identities, and surfaces risk in real time. The company also promotes open standards for managing AI-to-application connectivity through extended OAuth mechanisms.
For enterprises rapidly deploying AI agents internally, identity-centric AI security becomes essential.
Best for: Organisations deploying AI agents at scale that require identity governance for non-human actors.
Comparison Overview
| Vendor | Core strength | Ideal buyer |
| Check Point | Unified AI security across infrastructure and usage | Large enterprises seeking platform consolidation |
| CrowdStrike | Endpoint-integrated AI threat detection | Falcon-centric organisations |
| Cisco | Network-layer AI traffic visibility | Cisco ecosystem enterprises |
| Microsoft | Signal scale and Copilot integration | Microsoft 365-heavy environments |
| Okta | AI identity governance | Organisations deploying AI agents broadly |
How to choose the right AI security solution
Selecting the right AI security platform depends on architecture and maturity.
Organisations building AI internally should prioritise infrastructure protection and identity governance. Enterprises concerned with employee generative AI usage should evaluate prompt monitoring and DLP integration. Security teams overwhelmed by alert volume may prioritise AI-augmented SOC automation.
AI security is not a separate silo. It intersects with network security, identity management, cloud governance, and incident response.
The platforms above represent different strategic entry points into AI risk management. The best solution is the one aligned with your existing ecosystem and operational model.
In 2026, AI is both a tool and a target. Enterprises that treat AI security as an integrated part of their security architecture will be better positioned to manage evolving threats.
Image source: Pixabay
The post Best AI security solutions 2026: Top enterprise platforms compared appeared first on AI News.
-
(Multiomics OR Omics) AND (Pancreatic)
-
Unraveling pancreatic ductal adenocarcinoma at single-cell resolution with spatial insights: From mechanisms to clinical translation
Cancer Lett. 2026 Feb 28;645:218391. doi: 10.1016/j.canlet.2026.218391. Online ahead of print.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, characterized by pronounced cellular heterogeneity, a dense desmoplastic stroma, and a highly immunosuppressive tumor microenvironment (TME). Recent advances in single-cell RNA sequencing (scRNA-seq) have reshaped our understanding of PDAC by characterizing its cellular composition at single-cell resolution. These st
Unraveling pancreatic ductal adenocarcinoma at single-cell resolution with spatial insights: From mechanisms to clinical translation
Cancer Lett. 2026 Feb 28;645:218391. doi: 10.1016/j.canlet.2026.218391. Online ahead of print.
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, characterized by pronounced cellular heterogeneity, a dense desmoplastic stroma, and a highly immunosuppressive tumor microenvironment (TME). Recent advances in single-cell RNA sequencing (scRNA-seq) have reshaped our understanding of PDAC by characterizing its cellular composition at single-cell resolution. These studies have uncovered complex TME networks involving T cells, myeloid populations, fibroblasts, and malignant epithelial cells, and have provided mechanistic insights into immune evasion, metastatic progression, and therapeutic resistance. Collectively, these findings depict PDAC as a dynamic and interactive ecosystem driven by cellular interactions. In this review, we systematically summarize recent scRNA-seq-based studies addressing PDAC heterogeneity, tumorigenesis, immune remodeling, therapeutic resistance and biomarker discovery. We further discuss integrative single-cell and spatial multi-omics approaches to map the TME of PDAC, providing a framework for understanding PDAC biology at single-cell and spatial resolution.
PMID:41771343 | DOI:10.1016/j.canlet.2026.218391